Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Lipid management in patients with coronary artery disease by a clinical pharmacy service in a group model health maintenance organization.

Olson KL, Rasmussen J, Sandhoff BG, Merenich JA; Clinical Pharmacy Cardiac Risk Service Study Group.

Arch Intern Med. 2005 Jan 10;165(1):49-54.

PMID:
15642874
2.

Outcomes of patients discharged from pharmacy-managed cardiovascular disease management.

Olson KL, Delate T, Rasmussen J, Humphries TL, Merenich JA; Clinical Pharmacy Cardiac Risk Service Study Group.

Am J Manag Care. 2009 Aug;15(8):497-503.

5.

Clinical pharmacy cardiac risk service for managing patients with coronary artery disease in a health maintenance organization.

Sandhoff BG, Nies LK, Olson KL, Nash JD, Rasmussen JR, Merenich JA.

Am J Health Syst Pharm. 2007 Jan 1;64(1):77-84.

PMID:
17189584
7.

Clinical impact of a pharmacist-physician co-managed programme on hyperlipidaemia management in Hong Kong.

Lee VW, Fan CS, Li AW, Chau AC.

J Clin Pharm Ther. 2009 Aug;34(4):407-14. doi: 10.1111/j.1365-2710.2009.01024.x.

PMID:
19583673
8.
9.

Effectiveness of aggressive management of dyslipidemia in a collaborative-care practice model.

Ryan MJ Jr, Gibson J, Simmons P, Stanek E.

Am J Cardiol. 2003 Jun 15;91(12):1427-31.

PMID:
12804728
10.

Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.

Harikrishnan S, Rajeev E, Tharakan JA, Titus T, Ajit Kumar VK, Sivasankaran S, Krishnamoorthy KM, Nair K.

Indian Heart J. 2008 May-Jun;60(3):215-22.

PMID:
19240310
11.

[Improved coronary vasodilator capacity by drug lipid lowering therapy in patients in the early stage of coronary atherosclerosis with reduced coronary reserves and moderate LDL hypercholesteremia].

Baller D, Gleichmann U, Notohamiprodjo G, Weise R, Holzinger J, Montanus H, Betker S, Lehmann J.

Z Kardiol. 1998;87 Suppl 2:136-44. German.

PMID:
9827472
12.
13.

Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP).

Fonarow GC, Gawlinski A, Moughrabi S, Tillisch JH.

Am J Cardiol. 2001 Apr 1;87(7):819-22.

PMID:
11274933
15.

The A-SACT (Achievement in Singapore of Cholesterol Targets) study in patients with coronary heart disease.

Ho KT, Chin KW, Ng KS, Alemao E, Rajagopalan S, Yin D.

Am J Cardiovasc Drugs. 2006;6(6):383-91.

PMID:
17192128
16.

Achieving cholesterol target in a managed care organization (ACTION) trial.

Straka RJ, Taheri R, Cooper SL, Smith JC.

Pharmacotherapy. 2005 Mar;25(3):360-71.

PMID:
15843283
17.
18.

Achievement of optimal combined lipid values in a managed care setting: is a new treatment paradigm needed?

Sarawate CA, Cziraky MJ, Stanek EJ, Willey VJ, Corbelli JC, Charland SL.

Clin Ther. 2007 Jan;29(1):196-209.

PMID:
17379061
19.

Supplemental Content

Support Center